Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.dld.2023.11.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic drug monitoring in inflammatory bowel disease: recent developments.
Expert Rev Gastroenterol Hepatol
October 2024
Department of Gastroenterology, Alfred Health and Monash University, Melbourne, Australia.
Article Synopsis
- Therapeutic Drug Monitoring (TDM) is crucial for managing inflammatory bowel disease (IBD) patients on infliximab (IFX) or adalimumab, especially when there's a loss of response to these treatments; however, TDM isn't recommended for other biologic therapies.
- A review of literature indicates that TDM might be beneficial for IFX subcutaneous (SC) use, while it's not effective for golimumab, and findings on vedolizumab are inconsistent; ustekinumab shows some promise, but less so than anti-TNF agents.
- Recent advancements suggest that using dashboard systems for precision dosing of anti-TNF agents could optimize treatment, emphasizing a proactive approach to TDM.
Monotherapy or combination therapy in PsA: current aspects.
Ther Adv Musculoskelet Dis
September 2024
Department of Rheumatology, Fourth Department of Internal Medicine, Hippokration Hospital, Aristoteleio Panepistemio Thessalonikes, Thessaloniki, Greece.
Psoriatic arthritis (PsA) is an immune-mediated inflammatory disease with heterogeneity regarding its clinical features, mainly affecting the skin and the musculoskeletal system; additionally, extra-musculoskeletal manifestations and comorbidities are common, adding complexity to its treatment. In the last decades, a plethora of therapeutic options have been available, including conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs), biological DMARDs (bDMARDs), and targeted synthetic DMARDs (tsDMARDs), and many recommendations have been published regarding the proper use of them in patients with PsA. In rheumatoid arthritis, the combination of conventional with bDMARDs or tsDMARDs is a common and recommended practice, whereas in PsA there is scarce data about the benefit of this combination.
View Article and Find Full Text PDFEmerging Role of Biologic Drugs Targeting IL-17 and IL-23: Pityriasis Rubra Pilaris.
Life (Basel)
July 2024
Section of Dermatology-Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Napoli, Italy.
Article Synopsis
- Pityriasis rubra pilaris (PRP) is a rare skin disease that causes red and scaly patches, making it hard to treat.
- Because PRP is uncommon and can sometimes get better on its own, studying how to treat it is tricky.
- New medicines that target specific parts of the immune system, like IL-17 and IL-23, have shown some promise for treating PRP, but more research is needed to understand how well they work.
Anti-IL23/12 agents and JAK inhibitors for inflammatory bowel disease.
Front Immunol
August 2024
Laboratory of Human Disease and Immunotherapies, West China Hospital, Sichuan University, Chengdu, China.
IBD (inflammatory bowel disease) is a chronic inflammatory disease of the gastrointestinal tract with increasing incidence worldwide. Multiple factors, such as genetic background, environmental and luminal factors, and mucosal immune dysregulation, have been implicated in the cause of IBD, although the cause of the disease remains unknown. IL-12 and IL-23 and their downstream signaling pathways participate in the pathogenesis of inflammatory bowel disease.
View Article and Find Full Text PDFAnti-IL23 in inflammatory bowel disease patients with dermatological indication: The shared gastroenterological-dermatological clinic experience.
Dig Liver Dis
January 2024
Department of Medical Sciences, Gastroenterological Clinic, University of Turin, Turin, Italy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!